As CHD is the primary cause of death in most industrialized countries, and death at older ages is increasingly dominated by inflammation‐related diseases, the fact that allelic variation in FOXO3 is now known to significantly modify this risk has important clinical implications, especially in high risk patient populations, such as those with type 2 diabetes (Gregg et al., 2014) and obesity (Olshansky et al., 2005). Here, FOXO3 is linked to obesity due to melanocortin 4 receptor deficiency.